FDA Inspection 1327596 — Nand Singh, M.D.
The FDA completed an inspection of Nand Singh, M.D. on Jun 19, 2026 in Ruddington. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 19, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Ruddington (United Kingdom)
Additional Details
Clinical BA/BE